This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Achieve Life Sciences (ACHV), Harmony Biosciences Holdings (HRMY)

Tipranks - Tipranks - Wed Jun 24, 2:44PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV) and Harmony Biosciences Holdings (HRMY) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

Achieve Life Sciences (ACHV)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Achieve Life Sciences, with a price target of $10.00. The company’s shares closed last Tuesday at $4.96.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.8% and a 29.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as NeOnc Technologies Holdings, Inc., Reviva Pharmaceuticals Holdings, and SELLAS Life Sciences Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $13.20 average price target, which is a 165.1% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Harmony Biosciences Holdings (HRMY)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Harmony Biosciences Holdings today and set a price target of $55.00. The company’s shares closed last Tuesday at $34.08.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 25.2% and a 51.2% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Alto Neuroscience, Inc., and Definium Therapeutics. ;'>

Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $49.50, which is a 47.0% upside from current levels. In a report issued on June 11, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $42.00 price target.

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).